Skip to main content
Top
Published in: Inflammation 4/2019

01-08-2019 | Cytokines | ORIGINAL ARTICLE

Tizoxanide Inhibits Inflammation in LPS-Activated RAW264.7 Macrophages via the Suppression of NF-κB and MAPK Activation

Authors: Jiaoqin Shou, Xiangzhen Kong, Xiaoyang Wang, Ying Tang, Chunmei Wang, Mi Wang, Lifang Zhang, Yingchun Liu, Chenzhong Fei, Feiqun Xue, Juan Li, Keyu Zhang

Published in: Inflammation | Issue 4/2019

Login to get access

Abstract

Tizoxanide is the main active metabolite of nitazoxanide. Nitazoxanide and tizoxanide have a broad-spectrum anti-infective effect, including parasites, bacteria, and virus. In the present study, we investigated the anti-inflammatory effect of tizoxanide on lipopolysaccharide (LPS)-stimulated RAW264.7 cells and revealed underlying molecular mechanisms. The results showed that tizoxanide significantly suppressed production of NO as well as pro-inflammatory cytokines, such as IL-1β, IL-6, and TNF-α in dose-dependent manner. Meanwhile, the levels of gene expression of these cytokines were inhibited significantly by tizoxanide that was discovered using RT-PCR. The increased protein levels of inducible nitric oxide synthase, heme oxygenase-1, and cyclooxygenase-2 by LPS in the cells were also reduced by tizoxanide. Moreover, we found that tizoxanide inhibited the phosphorylation of IKK-α and degradation of IκB by LPS in macrophage cells. The increased protein levels of p65 induced by LPS in the cytoplasm and nucleus were both decreased by tizoxanide, and the nuclear translocation of p65 was also restrained in cell imaging. In addition, tizoxanide considerably also inhibited LPS-activated JNK, p38, and ERK phosphorylation in RAW264.7 cells. Taken together, our results suggested that tizoxanide exerts anti-inflammatory effects, by inhibiting the production of pro-inflammatory cytokines and suppressing of the activation of the NF-κB and the MAPK signaling pathways in LPS-treated macrophage cells.
Literature
1.
go back to reference Howard, M.D., E.D. Hood, B. Zern, V.V. Shuvaev, T. Grosser, and V.R. Muzykantov. 2014. Nanocarriers for vascular delivery of anti-inflammatory agents. Annual Review of Pharmacology and Toxicology 54: 205–226.CrossRef Howard, M.D., E.D. Hood, B. Zern, V.V. Shuvaev, T. Grosser, and V.R. Muzykantov. 2014. Nanocarriers for vascular delivery of anti-inflammatory agents. Annual Review of Pharmacology and Toxicology 54: 205–226.CrossRef
2.
go back to reference Roy, A., M. Srivastava, U. Saqib, D. Liu, S.M. Faisal, S. Sugathan, S. Bishnoi, and M.S. Baig. 2016. Potential therapeutic targets for inflammation in toll-like receptor 4 (TLR4)–mediated signaling pathways. International Immunopharmacology 40: 79–89.CrossRef Roy, A., M. Srivastava, U. Saqib, D. Liu, S.M. Faisal, S. Sugathan, S. Bishnoi, and M.S. Baig. 2016. Potential therapeutic targets for inflammation in toll-like receptor 4 (TLR4)–mediated signaling pathways. International Immunopharmacology 40: 79–89.CrossRef
3.
go back to reference Xiang, P., T. Chen, Y. Mou, H. Wu, P. Xie, G. Lu, X. Gong, Q. Hu, Y. Zhang, and H. Ji. 2015. NZ suppresses TLR4/NF-κB signalings and NLRP3 inflammasome activation in LPS-induced RAW264.7 macrophages. Inflammation Research 64: 799–808.CrossRef Xiang, P., T. Chen, Y. Mou, H. Wu, P. Xie, G. Lu, X. Gong, Q. Hu, Y. Zhang, and H. Ji. 2015. NZ suppresses TLR4/NF-κB signalings and NLRP3 inflammasome activation in LPS-induced RAW264.7 macrophages. Inflammation Research 64: 799–808.CrossRef
4.
go back to reference González, Y., D. Torres-Mendoza, G.E. Jones, and P.L. Fernandez. 2015. Marine diterpenoids as potential anti-inflammatory agents. Mediators of Inflammation 2015: 263543.CrossRef González, Y., D. Torres-Mendoza, G.E. Jones, and P.L. Fernandez. 2015. Marine diterpenoids as potential anti-inflammatory agents. Mediators of Inflammation 2015: 263543.CrossRef
5.
go back to reference Liang, N., Y. Sang, W. Liu, W. Yu, and X. Wang. 2018. Anti-inflammatory effects of gingerol on lipopolysaccharide-stimulated RAW 264.7 cells by inhibiting NF-κB signaling pathway. Inflammation 41 (3): 835–845.CrossRef Liang, N., Y. Sang, W. Liu, W. Yu, and X. Wang. 2018. Anti-inflammatory effects of gingerol on lipopolysaccharide-stimulated RAW 264.7 cells by inhibiting NF-κB signaling pathway. Inflammation 41 (3): 835–845.CrossRef
6.
go back to reference Putker, F., M.P. Bos, and J. Tommassen. 2015. Transport of lipopolysaccharide to the gram-negative bacterial cell surface. FEMS Microbiology Reviews 39: 985–1002.CrossRef Putker, F., M.P. Bos, and J. Tommassen. 2015. Transport of lipopolysaccharide to the gram-negative bacterial cell surface. FEMS Microbiology Reviews 39: 985–1002.CrossRef
7.
go back to reference Piazza, M., V. Calabrese, C. Baruffa, T. Gioannini, J. Weiss, and F. Peri. 2010. The cationic amphiphile 3,4-bis(tetradecyloxy)benzylamine inhibits LPS signaling by competing with endotoxin for CD14 binding. Biochemical Pharmacology 80: 2050–2056.CrossRef Piazza, M., V. Calabrese, C. Baruffa, T. Gioannini, J. Weiss, and F. Peri. 2010. The cationic amphiphile 3,4-bis(tetradecyloxy)benzylamine inhibits LPS signaling by competing with endotoxin for CD14 binding. Biochemical Pharmacology 80: 2050–2056.CrossRef
8.
go back to reference Rosadini, C.V., and J.C. Kagan. 2017. Early innate immune responses to bacterial LPS. Current Opinion in Immunology 44: 14–19.CrossRef Rosadini, C.V., and J.C. Kagan. 2017. Early innate immune responses to bacterial LPS. Current Opinion in Immunology 44: 14–19.CrossRef
9.
go back to reference Poltorak, A., X. He, I. Smirnova, M.Y. Liu, C. Van Huffel, et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282: 2085–2088.CrossRef Poltorak, A., X. He, I. Smirnova, M.Y. Liu, C. Van Huffel, et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282: 2085–2088.CrossRef
10.
go back to reference Tan, Y., and J.C. Kagan. 2014. A cross-disciplinary perspective on the innate immune responses to bacterial lipopolysaccharide. Molecular Cell 54: 212–223.CrossRef Tan, Y., and J.C. Kagan. 2014. A cross-disciplinary perspective on the innate immune responses to bacterial lipopolysaccharide. Molecular Cell 54: 212–223.CrossRef
11.
go back to reference Maeda, S., and M. Omata. 2008. Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Science 99: 836–842.CrossRef Maeda, S., and M. Omata. 2008. Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Science 99: 836–842.CrossRef
12.
go back to reference Lai, J.L., Y.H. Liu, C. Liu, M.P. Qi, R.N. Liu, X.F. Zhu, Q.G. Zhou, Y.Y. Chen, A.Z. Guo, and C.M. Hu. 2017. Indirubin inhibits LPS-induced inflammation via TLR4 abrogation mediated by the NF-kB and MAPK signaling pathways. Inflammation 40 (1): 1–12.CrossRef Lai, J.L., Y.H. Liu, C. Liu, M.P. Qi, R.N. Liu, X.F. Zhu, Q.G. Zhou, Y.Y. Chen, A.Z. Guo, and C.M. Hu. 2017. Indirubin inhibits LPS-induced inflammation via TLR4 abrogation mediated by the NF-kB and MAPK signaling pathways. Inflammation 40 (1): 1–12.CrossRef
13.
go back to reference Aggarwal, B.B. 2004. Nuclear factor-kappaB: the enemy within. Cancer Cell 6: 203–208.CrossRef Aggarwal, B.B. 2004. Nuclear factor-kappaB: the enemy within. Cancer Cell 6: 203–208.CrossRef
14.
go back to reference Olivera, A., T.W. Moore, F. Hu, A.P. Brown, A. Sun, D.C. Liotta, J.P. Snyder, Y. Yoon, H. Shim, A.I. Marcus, A.H. Miller, and T.W.W. Pace. 2012. Inhibition of the NF-κB signaling pathway by the curcumin analog, 3,5-Bis(2-pyridinylmethylidene)-4-piperidone (EF31): anti-inflammatory and anti-cancer properties. International Immunopharmacology 12: 368–377.CrossRef Olivera, A., T.W. Moore, F. Hu, A.P. Brown, A. Sun, D.C. Liotta, J.P. Snyder, Y. Yoon, H. Shim, A.I. Marcus, A.H. Miller, and T.W.W. Pace. 2012. Inhibition of the NF-κB signaling pathway by the curcumin analog, 3,5-Bis(2-pyridinylmethylidene)-4-piperidone (EF31): anti-inflammatory and anti-cancer properties. International Immunopharmacology 12: 368–377.CrossRef
15.
go back to reference Somvanshi, V.S., B.L. Ellis, Y. Hu, and R.V. Aroian. 2014. Nitazoxanide: nematicidal mode of action and drug combination studies. Molecular and Biochemical Parasitology 193: 1–8.CrossRef Somvanshi, V.S., B.L. Ellis, Y. Hu, and R.V. Aroian. 2014. Nitazoxanide: nematicidal mode of action and drug combination studies. Molecular and Biochemical Parasitology 193: 1–8.CrossRef
16.
go back to reference Harausz, E.P., K.A. Chervenak, C.E. Good, M.R. Jacobs, R.S. Wallis, M. Sanchez-Felix, W.H. Boom, and TB Research Unit (TBRU) at Case Western Reserve University. 2016. Activity of nitazoxanide and tizoxanide against Mycobacterium tuberculosis in vitro and in whole blood culture. Tuberculosis (Edinburgh, Scotland) 98: 92–96.CrossRef Harausz, E.P., K.A. Chervenak, C.E. Good, M.R. Jacobs, R.S. Wallis, M. Sanchez-Felix, W.H. Boom, and TB Research Unit (TBRU) at Case Western Reserve University. 2016. Activity of nitazoxanide and tizoxanide against Mycobacterium tuberculosis in vitro and in whole blood culture. Tuberculosis (Edinburgh, Scotland) 98: 92–96.CrossRef
17.
go back to reference Stachulski, A.V., C. Pidathala, E.C. Row, R. Sharma, N.G. Berry, M. Iqbal, J. Bentley, S.A. Allman, G. Edwards, A. Helm, J. Hellier, B.E. Korba, J.E. Semple, and J.F. Rossignol. 2011. Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication. Journal of Medicinal Chemistry 54: 4119–4132.CrossRef Stachulski, A.V., C. Pidathala, E.C. Row, R. Sharma, N.G. Berry, M. Iqbal, J. Bentley, S.A. Allman, G. Edwards, A. Helm, J. Hellier, B.E. Korba, J.E. Semple, and J.F. Rossignol. 2011. Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication. Journal of Medicinal Chemistry 54: 4119–4132.CrossRef
18.
go back to reference Fox, L.M., and L.D. Saravolatz. 2005. Nitazoxanide: a new thiazolide antiparasitic agent. Clinical Infectious Diseases 40: 1173–1180.CrossRef Fox, L.M., and L.D. Saravolatz. 2005. Nitazoxanide: a new thiazolide antiparasitic agent. Clinical Infectious Diseases 40: 1173–1180.CrossRef
19.
go back to reference Tchouaffi-Nana, F., T.E. Ballard, C.H. Cary, T.L. Macdonald, C.D. Sifri, and P.S. Hoffman. 2010. Nitazoxanide inhibits biofilm formation by staphylococcus epidermidis by blocking accumulation on surfaces. Antimicrobial Agents and Chemotherapy 54: 2767–2774.CrossRef Tchouaffi-Nana, F., T.E. Ballard, C.H. Cary, T.L. Macdonald, C.D. Sifri, and P.S. Hoffman. 2010. Nitazoxanide inhibits biofilm formation by staphylococcus epidermidis by blocking accumulation on surfaces. Antimicrobial Agents and Chemotherapy 54: 2767–2774.CrossRef
20.
go back to reference Dubreuil, L., I. Houcke, Y. Mouton, and J.F. Rossignol. 1996. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrobial Agents and Chemotherapy 40: 2266–2270.CrossRef Dubreuil, L., I. Houcke, Y. Mouton, and J.F. Rossignol. 1996. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrobial Agents and Chemotherapy 40: 2266–2270.CrossRef
21.
go back to reference La Frazia, S., A. Ciucci, F. Arnoldi, M. Coira, P. Gianferretti, M. Angelini, et al. 2013. Thiazolides, a new class of antiviral agents effective against rotavirus infection, target viral morphogenesis, inhibiting viroplasm formation. Journal of Virology 87: 11096–11106.CrossRef La Frazia, S., A. Ciucci, F. Arnoldi, M. Coira, P. Gianferretti, M. Angelini, et al. 2013. Thiazolides, a new class of antiviral agents effective against rotavirus infection, target viral morphogenesis, inhibiting viroplasm formation. Journal of Virology 87: 11096–11106.CrossRef
22.
go back to reference Rossignol, J.F., S. La Frazia, L. Chiappa, A. Ciucci, and M.G. Santoro. 2009. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. The Journal of Biological Chemistry 284: 29798–29808.CrossRef Rossignol, J.F., S. La Frazia, L. Chiappa, A. Ciucci, and M.G. Santoro. 2009. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. The Journal of Biological Chemistry 284: 29798–29808.CrossRef
23.
go back to reference Belardo, G., O. Cenciarelli, S. La Frazia, J.F. Rossignol, and M.G. Santoro. 2015. Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro. Antimicrobial Agents and Chemotherapy 59: 1061–1069.CrossRef Belardo, G., O. Cenciarelli, S. La Frazia, J.F. Rossignol, and M.G. Santoro. 2015. Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro. Antimicrobial Agents and Chemotherapy 59: 1061–1069.CrossRef
24.
go back to reference Rossignol, J.F. 2014. Review: Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Research 110: 94–103.CrossRef Rossignol, J.F. 2014. Review: Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Research 110: 94–103.CrossRef
25.
go back to reference Stockis, A., A.M. Aleemon, S. De Bruyn, and C. Gengler. 2002. NTZ pharmacokinetics and tolerability in man using single ascending oral doses. International Journal of Clinical Pharmacology and Therapeutics 40: 213–220.CrossRef Stockis, A., A.M. Aleemon, S. De Bruyn, and C. Gengler. 2002. NTZ pharmacokinetics and tolerability in man using single ascending oral doses. International Journal of Clinical Pharmacology and Therapeutics 40: 213–220.CrossRef
26.
go back to reference Lam, K.K., X. Zheng, R. Forestieri, A.D. Balgi, M. Nodwell, S. Vollett, et al. 2012. Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and intracellular proliferation of Mycobacterium tuberculosis. PLoS Pathogens 8: e1002691.CrossRef Lam, K.K., X. Zheng, R. Forestieri, A.D. Balgi, M. Nodwell, S. Vollett, et al. 2012. Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and intracellular proliferation of Mycobacterium tuberculosis. PLoS Pathogens 8: e1002691.CrossRef
27.
go back to reference Green, L.C., D.A. Wagner, J. Glogowski, P.L. Skipper, J.S. Wishnok, and S.R. Tannenbaum. 1982. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Analytical Biochemistry 126: 131–138.CrossRef Green, L.C., D.A. Wagner, J. Glogowski, P.L. Skipper, J.S. Wishnok, and S.R. Tannenbaum. 1982. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Analytical Biochemistry 126: 131–138.CrossRef
28.
go back to reference Mazzone, G.L., I. Rigato, and C. Tiribelli. 2010. Unconjugated bilirubin modulates nitric oxide production via iNOS regulation. Bioscience Trends 4: 244–248.PubMed Mazzone, G.L., I. Rigato, and C. Tiribelli. 2010. Unconjugated bilirubin modulates nitric oxide production via iNOS regulation. Bioscience Trends 4: 244–248.PubMed
29.
go back to reference Chen, T., Y. Mou, J. Tan, L. Wei, Y. Qiao, T. Wei, P. Xiang, S. Peng, Y. Zhang, Z. Huang, and H. Ji. 2015. The protective effect of CDDO-Me on lipopolysaccharide-induced acute lung injury in mice. International Immunopharmacology 25: 55–64.CrossRef Chen, T., Y. Mou, J. Tan, L. Wei, Y. Qiao, T. Wei, P. Xiang, S. Peng, Y. Zhang, Z. Huang, and H. Ji. 2015. The protective effect of CDDO-Me on lipopolysaccharide-induced acute lung injury in mice. International Immunopharmacology 25: 55–64.CrossRef
30.
go back to reference Akira, S., S. Uematsu, and O. Takeuchi. 2006. Pathogen recognition and innate immunity. Cell 124: 783–801.CrossRef Akira, S., S. Uematsu, and O. Takeuchi. 2006. Pathogen recognition and innate immunity. Cell 124: 783–801.CrossRef
31.
go back to reference Wynn, T.A., A. Chawla, and J.W. Pollard. 2013. Macrophage biology in development, homeostasis and disease. Nature 496: 445–455.CrossRef Wynn, T.A., A. Chawla, and J.W. Pollard. 2013. Macrophage biology in development, homeostasis and disease. Nature 496: 445–455.CrossRef
32.
go back to reference Baig, M.S., S.V. Zaichick, M. Mao, A.L. de Abreu, F.R. Bakhshi, P.C. Hart, U. Saqib, J. Deng, S. Chatterjee, M.L. Block, S.M. Vogel, A.B. Malik, M.E.L. Consolaro, J.W. Christman, R.D. Minshall, B.N. Gantner, and M.G. Bonini. 2015. NOS1-derived nitric oxide promotes NF-κB transcriptional activity through inhibition of suppressor of cytokine signaling-1. The Journal of Experimental Medicine 212: 1725–1738.CrossRef Baig, M.S., S.V. Zaichick, M. Mao, A.L. de Abreu, F.R. Bakhshi, P.C. Hart, U. Saqib, J. Deng, S. Chatterjee, M.L. Block, S.M. Vogel, A.B. Malik, M.E.L. Consolaro, J.W. Christman, R.D. Minshall, B.N. Gantner, and M.G. Bonini. 2015. NOS1-derived nitric oxide promotes NF-κB transcriptional activity through inhibition of suppressor of cytokine signaling-1. The Journal of Experimental Medicine 212: 1725–1738.CrossRef
33.
go back to reference Pankuch, G.A., and P.C. Appelbaum. 2006. Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic species. Antimicrobial Agents and Chemotherapy 50 (3): 1112–1117.CrossRef Pankuch, G.A., and P.C. Appelbaum. 2006. Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic species. Antimicrobial Agents and Chemotherapy 50 (3): 1112–1117.CrossRef
34.
go back to reference Buelow, R., S.G. Tullius, and H.D. Volk. 2001. Protection of grafts by hemoxygenase-1 and its toxic product carbon monoxide. American Journal of Transplantation 1: 313–315.CrossRef Buelow, R., S.G. Tullius, and H.D. Volk. 2001. Protection of grafts by hemoxygenase-1 and its toxic product carbon monoxide. American Journal of Transplantation 1: 313–315.CrossRef
35.
go back to reference Wei, Z.Y., K.Q. Chi, K.S. Wang, J. Wu, L.P. Liu, and H.R. Piao. 2018. Design, synthesis, evaluation, and molecular docking of ursolic acid derivatives containing a nitrogen heterocycle as anti-inflammatory agents. Bioorganic & Medicinal Chemistry Letters 28: 1797–1803.CrossRef Wei, Z.Y., K.Q. Chi, K.S. Wang, J. Wu, L.P. Liu, and H.R. Piao. 2018. Design, synthesis, evaluation, and molecular docking of ursolic acid derivatives containing a nitrogen heterocycle as anti-inflammatory agents. Bioorganic & Medicinal Chemistry Letters 28: 1797–1803.CrossRef
36.
go back to reference Jin, B., and H. Jin. 2018. Oxymatrine attenuates lipopolysaccharide-induced acute lung injury by activating the epithelial sodium channel and suppressing the JNK signaling pathway. Experimental Animals 67 (3): 337–347.CrossRef Jin, B., and H. Jin. 2018. Oxymatrine attenuates lipopolysaccharide-induced acute lung injury by activating the epithelial sodium channel and suppressing the JNK signaling pathway. Experimental Animals 67 (3): 337–347.CrossRef
37.
go back to reference Tumer, T.B., F.C. Onder, H. Ipek, T. Gungor, S. Savranoglu, et al. 2017. Biological evaluation and molecular docking studies of nitro benzamide derivatives with respect to in vitro anti-inflammatory activity. International Immunopharmacology 43: 129–139.CrossRef Tumer, T.B., F.C. Onder, H. Ipek, T. Gungor, S. Savranoglu, et al. 2017. Biological evaluation and molecular docking studies of nitro benzamide derivatives with respect to in vitro anti-inflammatory activity. International Immunopharmacology 43: 129–139.CrossRef
38.
go back to reference Tilmanis, D., C. van Baalen, D.Y. Oh, J.F. Rossignol, and A.C. Hurt. 2017. The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide. Antiviral Research 147: 142–148.CrossRef Tilmanis, D., C. van Baalen, D.Y. Oh, J.F. Rossignol, and A.C. Hurt. 2017. The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide. Antiviral Research 147: 142–148.CrossRef
39.
40.
go back to reference Wang, Y., Y. Cui, F. Cao, Y. Qin, W. Li, and J. Zhang. 2015. Ganglioside GD1a suppresses LPS-induced pro-inflammatory cytokines in RAW264.7 macrophages by reducing MAPKs and NF-kappaB signaling pathways through TLR4. International Immunopharmacology 28: 136–145.CrossRef Wang, Y., Y. Cui, F. Cao, Y. Qin, W. Li, and J. Zhang. 2015. Ganglioside GD1a suppresses LPS-induced pro-inflammatory cytokines in RAW264.7 macrophages by reducing MAPKs and NF-kappaB signaling pathways through TLR4. International Immunopharmacology 28: 136–145.CrossRef
41.
go back to reference Wu, X.F., Z.J. Ouyang, L.L. Feng, G. Chen, W.J. Guo, Y. Shen, X.D. Wu, Y. Sun, and Q. Xu. 2014. Suppression of NF-κB signaling and NLRP3 inflammasome activation in macrophages is responsible for the amelioration of experimental murine colitis by the natural compound fraxinellone. Toxicology and Applied Pharmacology 281: 146–156.CrossRef Wu, X.F., Z.J. Ouyang, L.L. Feng, G. Chen, W.J. Guo, Y. Shen, X.D. Wu, Y. Sun, and Q. Xu. 2014. Suppression of NF-κB signaling and NLRP3 inflammasome activation in macrophages is responsible for the amelioration of experimental murine colitis by the natural compound fraxinellone. Toxicology and Applied Pharmacology 281: 146–156.CrossRef
42.
go back to reference Hong, S.K., H.J. Kim, C.S. Song, I.S. Choi, J.B. Lee, and S.Y. Park. 2012. Nitazoxanide suppresses IL-6 production in LPS-stimulated mouse macrophages and TG-injected mice. International Immunopharmacology 13: 23–27.CrossRef Hong, S.K., H.J. Kim, C.S. Song, I.S. Choi, J.B. Lee, and S.Y. Park. 2012. Nitazoxanide suppresses IL-6 production in LPS-stimulated mouse macrophages and TG-injected mice. International Immunopharmacology 13: 23–27.CrossRef
43.
go back to reference Li, L., A. Hsu, and P.K. Moore. 2009. Actions and interactions of nitric oxide, carbon monoxide and hydrogen sulphide in the cardiovascular system and in inflammation--a tale of three gases! Pharmacology & Therapeutics 123: 386–400.CrossRef Li, L., A. Hsu, and P.K. Moore. 2009. Actions and interactions of nitric oxide, carbon monoxide and hydrogen sulphide in the cardiovascular system and in inflammation--a tale of three gases! Pharmacology & Therapeutics 123: 386–400.CrossRef
44.
go back to reference Schreiber, J., R.G. Jenner, H.L. Murray, G.K. Gerber, D.K. Gifford, and R.A. Young. 2006. Coordinated binding of NF-kappaB family members in the response of human cells to lipopolysaccharide. Proceedings of the National Academy of Sciences of the United States of America 103: 5899–5904.CrossRef Schreiber, J., R.G. Jenner, H.L. Murray, G.K. Gerber, D.K. Gifford, and R.A. Young. 2006. Coordinated binding of NF-kappaB family members in the response of human cells to lipopolysaccharide. Proceedings of the National Academy of Sciences of the United States of America 103: 5899–5904.CrossRef
45.
go back to reference Wang, T., X. Zhang, and J.J. Li. 2002. The role of NF-κB in the regulation of cell stress responses. International Immunopharmacology 2: 1509–1520.CrossRef Wang, T., X. Zhang, and J.J. Li. 2002. The role of NF-κB in the regulation of cell stress responses. International Immunopharmacology 2: 1509–1520.CrossRef
46.
go back to reference Kyriakis, J.M., and J. Avruch. 2012. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiological Reviews 92: 689–737.CrossRef Kyriakis, J.M., and J. Avruch. 2012. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiological Reviews 92: 689–737.CrossRef
Metadata
Title
Tizoxanide Inhibits Inflammation in LPS-Activated RAW264.7 Macrophages via the Suppression of NF-κB and MAPK Activation
Authors
Jiaoqin Shou
Xiangzhen Kong
Xiaoyang Wang
Ying Tang
Chunmei Wang
Mi Wang
Lifang Zhang
Yingchun Liu
Chenzhong Fei
Feiqun Xue
Juan Li
Keyu Zhang
Publication date
01-08-2019
Publisher
Springer US
Keyword
Cytokines
Published in
Inflammation / Issue 4/2019
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-019-00994-3

Other articles of this Issue 4/2019

Inflammation 4/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine